Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study, conducted by the Kenya Society for Hematology and Oncology, will develop a Breast Cancer and Care Registry (BRECC) for Kenya. Data on demographic, clinical and pathological characteristics, treatment and clinical outcome will be collected from newly diagnosed breast cancer patients. Breast cancer patients will be recruited into this registry cohort and followed up for a period of not less than five years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of breast cancer in Kenya | 5 years | |
| Breast cancer treatment patterns (drugs/dosage/schedule) in clinical practice in Kenya | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival | 5 years | |
| Overall survival | 5 years | |
| Patient demographics of breast cancer patients in Kenya |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Newly diagnosed breast cancer patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Nairobi School of Medicine; Internal Medicine and Therapeutics | Nairobi | 00202 | Kenya |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| Pathology: Prevalence of tumour types | 5 years |
| Correlation between risk factors and clinical outcome | 5 years |
| Therapy duration/compliance | 5 years |
| Safety: Incidence of adverse events | 5 years |
| D017437 |
| Skin and Connective Tissue Diseases |